B Rittenhouse

761 total citations
39 papers, 630 citations indexed

About

B Rittenhouse is a scholar working on Economics and Econometrics, Infectious Diseases and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, B Rittenhouse has authored 39 papers receiving a total of 630 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Economics and Econometrics, 8 papers in Infectious Diseases and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in B Rittenhouse's work include Health Systems, Economic Evaluations, Quality of Life (21 papers), Antimicrobial Resistance in Staphylococcus (8 papers) and Pharmaceutical Economics and Policy (8 papers). B Rittenhouse is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (21 papers), Antimicrobial Resistance in Staphylococcus (8 papers) and Pharmaceutical Economics and Policy (8 papers). B Rittenhouse collaborates with scholars based in United States, Saudi Arabia and Canada. B Rittenhouse's co-authors include Richard J. Willke, Michael J. Rybak, Manon Choinière, Henry A. Glick, Pierre Rousseau, Daniel Chartrand, Carolyn Pepler, Sylvie Perreault, Jim Z. Li and Andreas M. Pleil and has published in prestigious journals such as Critical Care Medicine, Journal of Clinical Epidemiology and Anesthesiology.

In The Last Decade

B Rittenhouse

37 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B Rittenhouse United States	15	278	189	162	112	108	39	630
Matthew J. Labreche United States	14	94 0.3×	64 0.3×	79 0.5×	24 0.2×	111 1.0×	16	515
Marilyn Steinberg Canada	18	443 1.6×	282 1.5×	137 0.8×	16 0.1×	359 3.3×	35	1.3k
Abdullah A. Alhifany Saudi Arabia	15	159 0.6×	52 0.3×	87 0.5×	39 0.3×	69 0.6×	61	553
Benoît Cossette Canada	12	250 0.9×	56 0.3×	135 0.8×	63 0.6×	244 2.3×	36	716
Víctor José González Ramallo Spain	14	134 0.5×	74 0.4×	89 0.5×	30 0.3×	231 2.1×	43	550
Roy Guharoy United States	11	79 0.3×	45 0.2×	50 0.3×	44 0.4×	45 0.4×	36	375
Christine U. Oramasionwu United States	15	264 0.9×	45 0.2×	42 0.3×	64 0.6×	295 2.7×	36	776
Vidya Menon United States	13	248 0.9×	35 0.2×	27 0.2×	38 0.3×	154 1.4×	39	644
Francis B. Palumbo United States	16	120 0.4×	11 0.1×	146 0.9×	104 0.9×	193 1.8×	42	783
Lucas Schulz United States	20	367 1.3×	317 1.7×	65 0.4×	21 0.2×	314 2.9×	77	1.1k

Countries citing papers authored by B Rittenhouse

Since Specialization

Citations

This map shows the geographic impact of B Rittenhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Rittenhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Rittenhouse more than expected).

Fields of papers citing papers by B Rittenhouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Rittenhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Rittenhouse. The network helps show where B Rittenhouse may publish in the future.

Co-authorship network of co-authors of B Rittenhouse

This figure shows the co-authorship network connecting the top 25 collaborators of B Rittenhouse. A scholar is included among the top collaborators of B Rittenhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Rittenhouse. B Rittenhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rittenhouse, B, et al.. (2024). Metformin in the Diabetes Prevention Program 3‐year trial: The cost‐effectiveness that never was. Diabetes Obesity and Metabolism. 26(11). 5097–5106.

Eguale, Tewodros, et al.. (2020). PDB27 THE DIABETES PREVENTION PROGRAM (DPP) QUALITY OF WELL BEING (QWB) UTILITY MEASURES AND MISSING DATA CONSIDERATIONS: AVAILABLE CASE ANALYSIS (ACA) VS. MANSKI LOWER AND UPPER BOUNDS (LMB AND UMB) RESULTS FOR UTILITIES AND QUALITY ADJUSTED LIFE YEARS (QALYS). Value in Health. 23. S112–S113.

Eguale, Tewodros, et al.. (2018). PDB82 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM (DPP) 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER QALY CALCULATIONS MAY REVIVE ITS METFORMIN CONCLUSIONS. Value in Health. 21. S132–S132. 1 indexed citations

Rittenhouse, B, et al.. (2018). Calculating Appropriate ICERS in Diabetes Prevention Program (DPP) Cost-Effectiveness and Overturning Misleading Conclusions Regarding Optimal Treatment. Value in Health. 21. S75–S75. 2 indexed citations

Eguale, Tewodros, et al.. (2018). PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALS. Value in Health. 21. S132–S133. 1 indexed citations

Rittenhouse, B, et al.. (2015). Exploring Cost-Effectiveness Heterogeneity By State: Using State-Level Vs. National Disease Incidence In Newborn Screening (Nbs) Cost-Effectiveness Analysis of Congenital Adrenal Hyperplasia (Cah). Value in Health. 18(7). A755–A756. 1 indexed citations

Alzarea, Abdulaziz Ibrahim, et al.. (2015). Re-Evaluating The Cost-Effectiveness of Screening For Congenital Adrenal Hyperplasia (Cah): The Sensitivity to Choice of Distributions In Probabilistic Sensitivity Analyses (Psas). Value in Health. 18(7). A668–A668. 1 indexed citations

Li, Jim Z., Richard J. Willke, B Rittenhouse, et al.. (2003). Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: Results from a multicenter trial. Clinical Therapeutics. 25(6). 1846–1871. 18 indexed citations

Willke, Richard J., et al.. (2003). Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial. Surgical Infections. 4(1). 57–70. 69 indexed citations

10.

Vinken, Angela G, et al.. (2003). Comparison of Linezolid With Oxacillin or Vancomycin in the Empiric Treatment of Cellulitis in US Hospitals. American Journal of Therapeutics. 10(4). 264–274. 24 indexed citations

11.

Willke, Richard J., Henry A. Glick, Jim Z. Li, & B Rittenhouse. (2002). Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis.. PubMed. 18(3). 540–54. 21 indexed citations

12.

Li, Zhiming, Richard J. Willke, Lionel Pinto, et al.. (2001). Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(3). 263–274. 114 indexed citations

13.

Vinken, Angela G, et al.. (2001). Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. Journal of Hospital Infection. 49. S13–S24. 24 indexed citations

14.

Rittenhouse, B & Manon Choinière. (1999). AN ECONOMIC EVALUATION OF PAIN THERAPY AFTER HYSTERECTOMY. International Journal of Technology Assessment in Health Care. 15(3). 548–562. 14 indexed citations

15.

Rittenhouse, B, Brian Dulisse, & Aaron A. Stinnett. (1999). At what price significance? The effect of price estimates on statistical inference in economic evaluation. Health Economics. 8(3). 213–219. 9 indexed citations

16.

Rittenhouse, B. (1996). Uses of Models in Economic Evaluations of Medicines and Other Health Technologies. OpenGrey (Institut de l'Information Scientifique et Technique). 24 indexed citations

17.

Rittenhouse, B. (1996). A Novel Compliance Assessment Technique: The Randomized Response Interview. International Journal of Technology Assessment in Health Care. 12(3). 498–510. 14 indexed citations

18.

Rittenhouse, B. (1995). The Relevance of Searching for Effects under a Clinical-trial Lamppost. Medical Decision Making. 15(4). 348–357. 11 indexed citations

19.

Rittenhouse, B. (1994). Teaching the Tools of Pharmaceutical Care Decision-Analysis. American Journal of Pharmaceutical Education. 58(4). 431–436. 1 indexed citations

20.

Grabenstein, John D., et al.. (1992). Community Pharmacists as Immunization Advocates. Medical Care. 30(6). 503–513. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact